Poupak Fallahi

Author PubWeight™ 72.72‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Thyroid disorders in chronic hepatitis C. Am J Med 2004 2.19
2 Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care 2005 1.83
3 Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. J Clin Endocrinol Metab 2010 1.68
4 IN PATIENTS WITH SUBCLINICAL HYPOTHYROIDISM WHILE IN THERAPY WITH TABLET L-T4, THE LIQUID L-T4 FORMULATION IS MORE EFFECTIVE IN RESTORING EUTHYROIDISM. Endocr Pract 2016 1.44
5 Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab 2009 1.30
6 Thyroid disorders in chronic hepatitis C virus infection. Thyroid 2006 1.21
7 Prevalence of hypothyroidism and Graves disease in sarcoidosis. Chest 2006 1.15
8 High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab 2004 1.11
9 Dedifferentiated thyroid cancer: a therapeutic challenge. Biomed Pharmacother 2008 1.08
10 Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2005 1.07
11 Thyroid cancer in systemic lupus erythematosus: a case-control study. J Clin Endocrinol Metab 2009 1.00
12 The administration of L-thyroxine as soft gel capsule or liquid solution. Expert Opin Drug Deliv 2014 1.00
13 Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. Clin Endocrinol (Oxf) 2006 0.99
14 Prevalence of thyroid dysfunctions in systemic lupus erythematosus. Metabolism 2009 0.98
15 Role of neck ultrasonography in the follow-up of children operated on for thyroid papillary cancer. Thyroid 2003 0.98
16 Increase of CXC chemokine CXCL10 and CC chemokine CCL2 serum levels in normal ageing. Cytokine 2006 0.96
17 Hepatitis C: thyroid dysfunction in patients with hepatitis C on IFN-alpha therapy. Nat Rev Gastroenterol Hepatol 2009 0.96
18 Changes in heart rate variability and QT dispersion in patients with overt hypothyroidism. Eur J Endocrinol 2008 0.94
19 High interleukin-6 and tumor necrosis factor-alpha serum levels in hepatitis C infection associated or not with mixed cryoglobulinemia. Clin Rheumatol 2009 0.94
20 New targeted therapies for thyroid cancer. Curr Genomics 2011 0.93
21 High values of CXCL10 serum levels in mixed cryoglobulinemia associated with hepatitis C infection. Am J Gastroenterol 2008 0.93
22 Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol 2006 0.90
23 High prevalence of thyroid autoimmunity and hypothyroidism in patients with psoriatic arthritis. J Rheumatol 2006 0.90
24 Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study. Thyroid 2007 0.89
25 Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2009 0.87
26 Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia. Autoimmun Rev 2008 0.87
27 Alpha-chemokine CXCL10 and beta-chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis. Metabolism 2008 0.87
28 RET TKI: potential role in thyroid cancers. Curr Oncol Rep 2012 0.86
29 Effect of PPAR-gamma activation and inhibition on glucose-stimulated insulin release in INS-1e cells. Diabetes 2004 0.86
30 Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests. Clin Endocrinol (Oxf) 2008 0.85
31 Serum levels of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor alpha in mixed cryoglobulinemia. Arthritis Rheum 2009 0.85
32 Clinical and subclinical autoimmune thyroid disorders in systemic sclerosis. Eur J Endocrinol 2007 0.84
33 B-cells and mixed cryoglobulinemia. Autoimmun Rev 2007 0.84
34 Circulating CXCL11 and CXCL10 are increased in hepatitis C-associated cryoglobulinemia in the presence of autoimmune thyroiditis. Mod Rheumatol 2011 0.84
35 CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes. J Clin Endocrinol Metab 2010 0.84
36 Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists. Cytokine 2010 0.83
37 Thyroid uptake of 67Ga-citrate is associated with thyroid autoimmunity and hypothyroidism in patients with sarcoidosis. Eur J Nucl Med Mol Imaging 2008 0.83
38 CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab 2014 0.83
39 Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection. Expert Rev Clin Immunol 2015 0.83
40 New targeted molecular therapies for dedifferentiated thyroid cancer. J Oncol 2010 0.83
41 Antibodies recognizing specific Mycobacterium avium subsp. paratuberculosis's MAP3738c protein in type 1 diabetes mellitus children are associated with serum Th1 (CXCL10) chemokine. Cytokine 2012 0.82
42 CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab 2012 0.82
43 High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis. Cytokine 2008 0.82
44 High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis. Autoimmunity 2008 0.82
45 New targeted therapies for anaplastic thyroid cancer. Anticancer Agents Med Chem 2012 0.81
46 Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells. Clin Endocrinol (Oxf) 2008 0.81
47 Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. Eur J Endocrinol 2008 0.81
48 N-terminal pro-brain natriuretic peptide and tumor necrosis factor-alpha both are increased in patients with Hepatitis C. J Interferon Cytokine Res 2010 0.81
49 Age-dependent changes in CXC chemokine ligand 10 serum levels in euthyroid subjects. J Interferon Cytokine Res 2005 0.80
50 Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10. Cytokine 2011 0.80
51 High circulating levels of N-terminal pro-brain natriuretic peptide and interleukin 6 in patients with mixed cryoglobulinemia. J Med Virol 2010 0.80
52 Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. Eur J Endocrinol 2005 0.79
53 Interferon-α, -β and -γ induce CXCL11 secretion in human thyrocytes: modulation by peroxisome proliferator-activated receptor γ agonists. Immunobiology 2012 0.79
54 Sorafenib in the treatment of thyroid cancer. Expert Rev Anticancer Ther 2015 0.79
55 Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer. Cytokine 2012 0.79
56 Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. Metabolism 2010 0.79
57 Increase of interferon-γ inducible CXCL9 and CXCL11 serum levels in patients with active Graves' disease and modulation by methimazole therapy. Thyroid 2013 0.79
58 Incidence of thyroid disorders in systemic sclerosis: results from a longitudinal follow-up. J Clin Endocrinol Metab 2013 0.78
59 Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists. Endocr Relat Cancer 2009 0.78
60 Lobectomy versus total thyroidectomy in children with post-Chernobyl thyroid cancer: a 15 year follow-up. Endocrine 2011 0.78
61 In vitro and in vivo study on the antioxidant activity of dexrazoxane. Biomed Pharmacother 2009 0.78
62 High serum levels of CXCL11 in mixed cryoglobulinemia are associated with increased circulating levels of interferon-γ. J Rheumatol 2011 0.78
63 Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL-6 is associated with high serum Th2 chemokine CCL2. Clin Rheumatol 2013 0.78
64 Serum concentrations of interleukin 1beta, CXCL10, and interferon-gamma in mixed cryoglobulinemia associated with hepatitis C infection. J Rheumatol 2009 0.78
65 Thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma in children. Surgery 2006 0.78
66 Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. J Clin Endocrinol Metab 2007 0.78
67 Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis. J Rheumatol 2008 0.78
68 Cytokines and HCV-related autoimmune disorders. Immunol Res 2014 0.77
69 CXCL10 and CCL2 chemokine serum levels in patients with hepatitis C associated with autoimmune thyroiditis. J Interferon Cytokine Res 2009 0.77
70 β (CCL2) and α (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-α agonists in Graves' ophthalmopathy. J Endocrinol 2012 0.77
71 Thyroid-associated ophthalmopathy and TSH receptor autoantibodies in nonmetastatic thyroid cancer after total thyroidectomy. Am J Med Sci 2008 0.77
72 Interleukin-1β, C-x-C motif ligand 10, and interferon-gamma serum levels in mixed cryoglobulinemia with or without autoimmune thyroiditis. J Interferon Cytokine Res 2010 0.77
73 Carotid integrated backscatter analysis in patients with subclinical hypothyroidism. Clin Endocrinol (Oxf) 2007 0.77
74 Peroxisome proliferator-activated receptor-α agonists modulate CXCL9 and CXCL11 chemokines in Graves' ophthalmopathy fibroblasts and preadipocytes. Mol Cell Endocrinol 2011 0.77
75 Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease. Exp Cell Res 2011 0.77
76 The presence of autoimmune thyroiditis in mixed cryoglobulinemia patients is associated with high levels of circulating interleukin-6, but not of tumor necrosis factor-alpha. Clin Exp Rheumatol 2011 0.77
77 Increased CXCL9 serum levels in hepatitis C-related mixed cryoglobulinemia, with autoimmune thyroiditis, associated with high levels of CXCL10. J Interferon Cytokine Res 2013 0.77
78 Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. J Clin Endocrinol Metab 2011 0.77
79 Induction of chromatid-type aberrations in peripheral lymphocytes of hospital workers exposed to very low doses of radiation. Mutat Res 2006 0.77
80 Chemokine (CXC motif) ligand 9 serum levels in mixed cryoglobulinaemia are associated with circulating levels of IFN-gamma and TNF-alpha. Clin Exp Rheumatol 2012 0.76
81 Prolonged in vitro exposure to autoantibodies against CD38 impairs the function and survival of human pancreatic islets. Diabetes 2002 0.76
82 Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer. Curr Med Chem 2016 0.76
83 CXCR3, CXCR5, CXCR6, and CXCR7 in Diabetes. Curr Drug Targets 2016 0.76
84 Targeting chemokine (C-X-C motif) receptor 3 in thyroid autoimmunity. Recent Pat Endocr Metab Immune Drug Discov 2014 0.76
85 Cabozantinib in Thyroid Cancer. Recent Pat Anticancer Drug Discov 2015 0.76
86 High circulating N-terminal pro-brain natriuretic peptide and tumor necrosis factor-alpha in mixed cryoglobulinemia. World J Gastroenterol 2009 0.75
87 Effect of telmisartan on QT interval variability and autonomic control in hypertensive patients with left ventricular hypertrophy. Biomed Pharmacother 2009 0.75
88 [Extrahepatic manifestations of hepatitis C virus: the thyroid disorders]. Recenti Prog Med 2005 0.75
89 High levels of circulating chemokine (C-X-C motif) ligand 11 are associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis and with chemokine (C-X-C motif) ligand 10. J Interferon Cytokine Res 2011 0.75
90 Systemic sclerosis fibroblasts show specific alterations of interferon-γ and tumor necrosis factor-α-induced modulation of interleukin 6 and chemokine ligand 2. J Rheumatol 2012 0.75
91 Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro and in Vivo in Papillary Dedifferentiated Thyroid Cancer. Endocrinology 2011 0.75
92 Analysis of chromosome damage in circulating lymphocytes of radiological workers affected by thyroid nodules. Mutat Res 2006 0.75
93 Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer. Mini Rev Med Chem 2015 0.75